Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 4 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) Overview | 7 | 1 |
| Therapeutics Development | 8 | 3 |
| Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) Products under Development by Stage of Development | 8 | 1 |
| Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) Products under Development by Therapy Area | 9 | 1 |
| Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) Products under Development by Indication | 10 | 1 |
| Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) Pipeline Products Glance | 11 | 2 |
| Late Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) Products under Development by Companies | 13 | 2 |
| Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) Products under Development by Universities/Institutes | 15 | 2 |
| Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) Therapeutics Assessment | 17 | 4 |
| Assessment by Monotherapy/Combination Products | 17 | 1 |
| Assessment by Mechanism of Action | 18 | 1 |
| Assessment by Route of Administration | 19 | 1 |
| Assessment by Molecule Type | 20 | 1 |
| Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) Companies Involved in Therapeutics Development | 21 | 7 |
| Amgen Inc. | 21 | 1 |
| Bristol-Myers Squibb Company | 22 | 1 |
| Chong Kun Dang Pharmaceutical Corp. | 23 | 1 |
| Japan Tobacco Inc. | 24 | 1 |
| Kowa Company, Ltd. | 25 | 1 |
| Merck &Co., Inc. | 26 | 1 |
| Pfizer Inc. | 27 | 1 |
| Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) Drug Profiles | 28 | 13 |
| AMG-899 Drug Profile | 28 | 2 |
| anacetrapib Drug Profile | 30 | 2 |
| BMS-795311 Drug Profile | 32 | 1 |
| CKD-519 Drug Profile | 33 | 1 |
| dalcetrapib Drug Profile | 34 | 4 |
| HL-16 Drug Profile | 38 | 1 |
| K-312 Drug Profile | 39 | 1 |
| PF-04445597 Drug Profile | 40 | 1 |
| Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) Dormant Projects | 41 | 1 |
| Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) Discontinued Products | 42 | 3 |
| Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) Featured News &Press Releases | 45 | 12 |
| Aug 23, 2016: DalCor Announces Opening of International Trial Sites for Its Dal-GenE Phase 3 Cardiovascular Outcomes Trial | 45 | 1 |
| Jul 18, 2016: DalCor Dalcetrapib Demonstrates Genotype-Dependent Effects on Cholesterol Efflux and Inflammation in Data Published by The Montreal Heart Institute in Circulation: Cardiovascular Genetics | 45 | 1 |
| Apr 26, 2016: DalCor Randomizes First Patient in the DalGenE Phase 3 Cardiovascular Outcomes Trial | 46 | 2 |
| Nov 13, 2015: Merck Provides Update on REVEAL Outcomes Study | 48 | 1 |
| Jun 08, 2015: DalCor Pharma licenses a late-stage investigational cardiovascular drug following major scientific discovery | 48 | 1 |
| Jun 03, 2015: Dezima Pharma s CETP Inhibitor, TA-8995, Phase 2b (TULIP) Study Results Published in The Lancet | 49 | 1 |
| Jan 12, 2015: A World First - Discovery of a personalized therapy for cardiovascular disease | 50 | 1 |
| Nov 13, 2014: Dezima Pharma Announces Complete Enrolment of CETP Inhibitor TA-8995 Study in Subjects With Isolated, Elevated Lipoprotein(a) Levels | 50 | 1 |
| Aug 29, 2014: Dezima Reports Positive Results in its Phase 2b TULIP Trial with CETP Inhibitor TA-8995 in Dyslipidemia | 51 | 1 |
| Jul 08, 2014: Dezima Pharma extends clinical development program for its CETP Inhibitor TA-8995 | 52 | 1 |
| Jan 13, 2014: Dezima Pharma Completes Patient Enrolment for TULIP Phase 2B Study with CETP Inhibitor TA-8995 | 52 | 1 |
| Aug 29, 2013: Dezima Pharma initiates Phase 2b TULIP study on CETP inhibitor program DEZ-001 | 53 | 1 |
| Nov 05, 2012: Roche's Dalcetrapib Increases HDL Levels But Fails To Reduce Risk Of Cardiovascular Events, Study Finds | 54 | 1 |
| Aug 26, 2012: Merck Provides Update On Anacetrapib Development Program | 55 | 1 |
| May 07, 2012: Roche Provides Update On Phase III Study Of Dalcetrapib | 55 | 2 |
| Appendix | 57 | 2 |
| Methodology | 57 | 1 |
| Coverage | 57 | 1 |
| Secondary Research | 57 | 1 |
| Primary Research | 57 | 1 |
| Expert Panel Validation | 57 | 1 |
| Contact Us | 57 | 1 |
| Disclaimer | 58 | 1 |